Cargando…

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors

OBJECTIVE: Recently, immune checkpoint inhibitor (ICI) treatment has shown encouraging performance in improving the prognosis of hepatocellular carcinoma (HCC) patients. The gut microbiome plays a vital role in altering the efficacy of ICIs, which may be impacted by antibiotics. The aim of the meta-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lilong, Chen, Chen, Chai, Dongqi, Li, Chunlei, Guan, Yongjun, Liu, Li, Kuang, Tianrui, Deng, Wenhong, Wang, Weixing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429218/ https://www.ncbi.nlm.nih.gov/pubmed/36059512 http://dx.doi.org/10.3389/fimmu.2022.956533

Ejemplares similares

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
por: Zhang, Lilong, et al.
Publicado: (2023)

Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma
por: Kuang, Tianrui, et al.
Publicado: (2023)

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors
por: Zhang, Lilong, et al.
Publicado: (2022)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy
por: Zhang, Lilong, et al.
Publicado: (2023)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Receptor-interacting protein in malignant digestive neoplasms
por: Zhang, Lilong, et al.
Publicado: (2021)

The Prognostic Significance and Potential Mechanism of Prolyl 3-Hydroxylase 1 in Hepatocellular Carcinoma
por: Li, Chunlei, et al.
Publicado: (2022)

The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
por: Zhang, Lilong, et al.
Publicado: (2020)

Systematic analysis of the role of SLC52A2 in multiple human cancers
por: Zhang, Lilong, et al.
Publicado: (2022)

Prognostic Value and Immunological Role of MORF4-Related Gene-Binding Protein in Human Cancers
por: Chai, Dongqi, et al.
Publicado: (2021)

Effects of hormones on intestinal stem cells
por: Liu, Li, et al.
Publicado: (2023)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Key Molecules of Fatty Acid Metabolism in Gastric Cancer
por: Li, Chunlei, et al.
Publicado: (2022)

Prognostic value of controlling nutritional status on clinical and survival outcomes in cancer patients treated with immunotherapy
por: Zhang, Jiacheng, et al.
Publicado: (2023)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

HBV-Induced Immune Imbalance in the Development of HCC
por: Chen, Yongyan, et al.
Publicado: (2019)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Shen, Jinhai, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors
por: Zhong, Chengqian, et al.
Publicado: (2022)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
por: Chen, Xian, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Xu, Shuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_frdavb3o6rgmqli236eavtm98r